U.S. Markets closed

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--

ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • 2018 Cantor Global Healthcare Conference
    October 2 at 2:50pm ET
  • Leerink Partners Roundtable Series
    October 3 at 9:30am ET

A webcast of each presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005831/en/